Common postzygotic mutational signature in multiple healthy adult tissues related to embryonic hypoxia

Yaqiang Hong[1,3,¶], Dake Zhang[1,2,¶], Xiangtian Zhou[4,5,¶], Aili Chen[1,¶], Amir Abliz[6,¶], Jian Bai[1], Liang Wang[7,8], Qingtao Hu[1], Kenan Gong[1], Xiaonan Guan[1,2], Mengfei Liu[6], Xinchang Zheng[1,2], Shujuan Lai[1], Hongzhu Qu[9], Fuxin Zhao[4,5], Shuang Hao[1], Zhen Wu[7,8], Hong Cai[6], Shaoyan Hu[10], Yue Ma[11], Junting Zhang[7,8], Yang Ke[6], Qianfei Wang[1], Wei Chen[1,2,*], Changqing Zeng[1,12,13,*]

[1] Key Laboratory of Genomic and Precision Medicine of Chinese Academy of Sciences, Beijing Institute of Genomics, Beijing, China

[2] Beijing Advanced Innovation Center for Biomedical Engineering, School of Biological Science and Medical Engineering, Beihang University, Beijing, China

[3] Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China

[4] School of Optometry and Ophthalmology and Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China

[5] State Key Laboratory Cultivation Base and Key Laboratory of Vision Science, Ministry of Health P. R. China and Zhejiang Provincial Key Laboratory of Ophthalmology and Optometry, Wenzhou, Zhejiang, China

[6] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Laboratory of Genetics, Peking University Cancer Hospital & Institute, Beijing, China

[7] Skull Base and Brainstem Tumor Division, Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China

[8] China National Clinical Research Center for Neurological Diseases, NCRC-ND, Beijing, China

[9] Key Laboratory of Genome Sciences and Information of Chinese Academy of Sciences, Beijing Institute of Genomics, Beijing, China

[10] Pediatrics, Hematology and Oncology, Children's Hospital of Soochow University, Soochow, Suzhou, China

[11] Institute of Biophysics, Chinese Academy of Sciences, Beijing, China

[12] Collaborative Innovation Center for Genetics and Development, Shanghai, China

[13] University of Chinese Academy of Sciences, Beijing, China

* Corresponding author

E-mail: chenw@big.ac.cn (WC) and czeng@big.ac.cn (CZ).

¶ These authors contributed equally to this work.

Abstract

Postzygotic mutations are acquired in all of the normal tissues throughout an individual's lifetime and hold clues for identifying mutagenesis causing factors. The process and underlying mechanism of postzygotic mutations in normal tissues is still poorly understood. In this study, we investigated postzygotic mutation spectra in healthy individuals by optimized ultra-deep exome sequencing of time series samples from the same volunteer and samples from different individuals. In cells of blood, sperm, and muscle, we resolved three common types of mutational signature. Two of them are known to represent clock-like mutational processes, and their proportions in mutation profiles associated with polymorphisms of epigenetic regulation genes, suggesting the contribution of personal genetic backgrounds to underlying biological process. Notably, the third signature, characterized by C>T transitions at GpCpN sites, tends to be a feature of diverse normal tissues. Mutations of this type were likely to occur early in embryo development even before the tissue differentiation, as indicated by their relatively high allele frequencies, sharing variants between multiple tissues, and lacking of age-related accumulation. Almost all tumors shown in public datasets did not have this signature detected except for 19.6% of clear cell renal cell carcinoma samples, which featured by activation of the hypoxia-induced signaling pathway. Moreover, in vitro activation of HIF signaling pathway successfully introduced the corresponding mutation profile of this signature in a culture-expanded human embryonic stem cell line. Therefore, embryonic hypoxia may explain this novel signature across multiple normal tissues. Our study suggest hypoxic conditions in the early stage of embryo development may be a crucial factor for the C>T transitions at GpCpN sites and individual genetic background also related to shaping human postzygotic mutation profiles.

Author Summary

The process and related mechanism of post-zygotic mutations in normal tissues is still poorly understood. By analyzing post-zygotic mutations in blood, sperm and muscle from healthy individuals, we found a normal tissues specific mutation type characterized by C>T transitions at GpCpN sites. Almost none of tumors in The Cancer Genome Atlas project harbors this type of mutations, except for a subset of clear cell renal cell carcinoma samples with higher activity of hypoxia inducible signaling pathways. We further

reproduce the enrichment of this type of mutations in human embryonic stem cells by specific activating hypoxia inducible factor 1α. Taken together, we propose that hypoxic conditions are one crucial factor responsible for the occurrence of post-zygotic mutations, especially the C>T transition in GpCpN sites, in the early stage of embryo development in healthy individuals.

Introduction

After fertilization, most genomic mutations typically occur as a result of replication errors, DNA structure instability, as well as other endogenous and exogenous sources, resulting in the genotypic and phenotypic heterogeneity of all types of cells in the body [1-3]. In particular, mutations can be triggered by distinct environmental factors, producing characteristic patterns. The accumulation of somatic mutations is believed to chronicle the exposures, toxicity, regeneration and clonal structure of the progresses from health to disease [4-6]. Thus, the roles of somatic mutations in pathogenesis have been widely explored [7, 8]. Moreover, in recent years, multiple cell clones with distinct genotypes, referred to as somatic mosaicism by lineage expansion in healthy tissues, have drawn attention to the factors underlying certain disorders [9, 10].

Tissue-specific processes or particular microenvironmental changes leave unique imprints in genomes [9, 11]. With the advent of next-generation sequencing (NGS), characteristics of multiple mutagenic processes have been revealed for the first time in tumors of various origins [7, 11-13]. For instance, smoking results mainly in C>A transitions in lung cancers, while ultraviolet (UV) radiation leaves a footprint involving CC>TT dinucleotide substitutions in skin cancers [7, 14]. A recent investigation showed distinct mutational spectra in cultured adult stem cells (ASCs) of liver in comparison with those originating from the colon and small intestine [9]. Moreover, mutation spectra are influenced by the genetic background of individuals. For example, breast cancer patients having *BRCA1* or *BRCA2* germline mutations showed a specific mutational signature in tumor genomes compared with patients carrying *BRCA* wild types [11]. The confounding of different mutagenesis-related factors by the genetic background means that mutation accumulation patterns differ among tissues and individuals.

Two mutational signatures (Signature 1 and Signature 5 in COSMIC) related to the deamination of methylated cytosines have shown a feature of accumulation with age in a broad range of cell types. However,

87 the accumulation process does not seem to maintain a steady pace. Specifically, the mutation rate per cell
88 division varies during development, undergoing diverse biological changes prenatally, and in childhood and
89 adulthood [1]. *De novo* mutations in offspring increase with paternal age, and the accumulation rate in gonads
90 was estimated to be ~2 mutations per year [15]. More than twofold differences in variation have been
91 observed between families, possibly influenced by germline methylation [1]. Hence, factors that influence
92 the mutagenic processes may differ due to various developmental demands, such as the activities of stem
93 cells in tissue repair, exposure to environmental factors, and tissue-specific functions [7, 9]. In addition, the
94 changes in mutational profile in cultured cells also reflect the genetic drift that occurs during clonal
95 expansion of the cell population carrying multiple pre-existing mutations [16].

96 The large majority of knowledge on somatic mutation has been obtained from genomic analyses of cancer
97 or noncancer diseases, animal models, and cultured cells. However, despite the importance of analyzing the
98 generation and subsequent effects of somatic mutations in normal tissues, studies on their mutation profiles
99 are limited due to not only difficulties in obtaining appropriate tissues from healthy individuals, but also the
100 scarcity of cells carrying mutations [17-19]. Although great effort has been made on analyzing somatic
101 mutation profile on various tissue including skin, liver, esophagus, and colon, our knowledge of the mutation
102 spectrum and its dynamic nature in healthy individuals remains inadequate [6, 10, 20, 21].

103 To obtain the somatic mutation spectrum in healthy individuals, in this study we first conducted optimized
104 ultra-deep exome sequencing (~800×) of blood samples in five trio families. From deep sequencing for time
105 points samples of blood, muscle and sperm in one subject, followed by comparison with results of another
106 50 samples, we identified a mutational signature characterized by C>T transition at GpCpN, specific to
107 normal tissues. Further association analysis suggested that certain SNPs residing in epigenetic regulators
108 may explain the individual-specific proportions of C>T at GpCpN in the population. An *in vitro* experiment
109 and somatic mutation data from cancer genome research further showed that hypoxia is a trigger for
110 mutagenesis.

111 Results

112 Postzygotic mutations in normal blood and sperm cells revealed by ultra-deep exome sequencing

113 We adopted ultra-deep exome sequencing (>800× coverage) to identify genomic mutations, with the benefits

114 of increased sensitivity and accuracy due to multiple steps of optimization (S1 Fig, Methods, S1 Appendix).
115 First, we analyzed five specimens from the volunteer M0038 annually for 4 years, including 2 blood and 3
116 sperm samples (S1 Table). In both tissues, one *de novo* mutation was identified and its variant allele fraction
117 (VAF) reached 0.4 +/- 0.02 in all samples. Overall, 36 cross-tissue mutations, with VAF of 0.002 to 0.434,
118 were shared by at least one blood and one sperm sample (Fig 1A, S2 Fig, and S2 Table). They were likely to
119 occur before tissue differentiation, considering the previous speculation that some cells may contribute to
120 multiple tissues at the early stages of embryo development [22]. For tissue-specific mutations, four common
121 postzygotic mutations were detected in all of the whole-blood samples, and 16 common mutations were seen
122 in all three sperm samples (Fig 1A-B). Especially, VAFs for these mutations were all consistent across the
123 samples.

124 **Fig. 1. Postzygotic mutation profiling.** (A) Schematic diagram depicting mutation accumulation among the time-point
125 samples from individual M0038. Each tested sample carries a couple of hundred mutations as private events (numbers at the
126 bottom). One *de novo* mutation occurred before fertilization (top). Thirty-six mutations were shared by at least one sperm
127 sample and one blood sample. In contrast with the 16 shared common mutations found in sperm samples but not in blood, and
128 only four blood specific mutations were shared by both ages in blood. (B) Shared mutated genes in different samples of M0038.
129 Among the 57 mutations revealed in at least two samples besides the *de novo* mutation (*CEP95*), only one mutation (*NF2*,
130 0.09) was identified to have an allele fraction greater than 0.05. The scaled color represents the allele fraction of mutations.
131 (C) Density plot of mutation fraction distribution. A significantly higher density was shown in the low-fraction region of all
132 samples (dashed pink area) and there were more mutations with low allele fractions than the mutations obtained by muscle
133 (light blue area with dotted line) and simulation (beige area with dashed line).

134 We further compared postzygotic mutation profiles in five trio families with this approach (including M0038).
135 Overall, 3,266 postzygotic mutations and 4 *de novo* mutations (Methods) in blood samples from children in
136 the five trios were detected with VAF ranging from 0.002 to 0.528 (S3 Fig, S3 Table), and the validation rate
137 was above 85% using multiple methods (Methods and S2 Appendix). Approximately 90% of the variations
138 in all individuals had allele fractions of less than 0.020, indicating that only a small subset of cells carried
139 the mutations. Based on the assumption that the mutation rate during cell divisions is stable, *in silico*
140 simulation [23, 24] showed a range of allele fractions from 0.050 to 0.200 (beige area in Fig 1C, S4 Fig, and
141 Methods), but our observations demonstrated a significant difference from the simulation ($p < 2.2\times10^{-16}$,
142 Kolmogorov–Smirnov test). This suggested the mutation rate may be unequal during cell divisions,
143 consistent with the findings in previous studies on embryonic development [1, 25]. Our sample size limited

144 the power to detect the relationship between amounts of postzygotic mutations and age, the former of which
145 varied from 124 to 813 (S1 Table). Besides, these mutations had low recurrence rates. On average, only 2.7
146 (range 0–7) mutations were shared by two individuals (S2 Fig), and none was found in more than two
147 individuals (S3 Table).

148

149 **Significant enrichment of GpCpN and NpCpG postzygotic mutations in normal tissues**

150 We summarized the trinucleotide composition of all 96 substitution types in each individual according to
151 their position and two neighboring bases. As demonstrated in Fig 2A, C>T transitions were enriched in all
152 individuals, of which more than 90% were in GpCpN or NpCpG sites in both blood and sperm cells (S5 Fig).
153 For these two trinucleotide contexts, only individual M0038 had more GpCpN than NpCpG mutations in all
154 types of samples, whereas the other individuals had more NpCpG mutations. This suggests the existence of
155 distinct mutational processes among individuals.

156 **Fig. 2. Patterns of postzygotic mutations in healthy individuals.** (A) Heat map of the rates of each mutation type. Significant
157 enrichment of C>T transitions, especially at NpCpG and GpCpN sites, was exhibited at each of the 96 mutated trinucleotides
158 in all individuals. Similar patterns were shown among various types of sample from individual M0038. C>A transversions
159 with no preferred context were also detected in normal cells. (B) Strand asymmetry of C>T transitions by analysis of the
160 replication direction. C>T transitions were more likely to occur in the left-replication regions and G>A were enriched in the
161 right-replication regions, suggesting mutational strand asymmetry due to replication. (C) The transcription asymmetry of C>T
162 transitions. C>T was also more likely to occur in regions with the sense strand as the encoded strand, whereas G>A exhibited
163 high enrichment in the opposite regions.

164 C>T transitions at NpCpG sites commonly originate from age-related spontaneous deamination of
165 methylated cytosine to thymine [2, 7]. Nevertheless, time-point samples for the individual M0038 did not
166 show the time-related feature of C>T transitions at NpCpG, with their proportions varying from 13% to 31%
167 (S6 Fig). Among other four individuals, their counts slightly increased with age but without any significance
168 (e.g., 94% in the youngest individual, 5-year-old M0074, and 95% in 22-year-old F0061; S6 Fig). Meanwhile,
169 the proportions of C>T at GpCpN were consistent across all samples, with the highest rate of 29% and the
170 lowest of 23% (S6 Fig).

171 Moreover, these mutations also demonstrated reported mutational strand asymmetries caused by replication

172 and transcription (Methods). For the C>T or G>A transition at GpCpN and NpCpG, the C>T transitions were
173 likely to occur in the left-replication regions of the genome during DNA replication, whereas more G>A
174 transitions occurred in the right-replication regions (Fig 2B and S7 Fig). The genomic regions that encoded
175 genes on the reference strand exhibited a high density of C>T transitions, and the regions that encoded genes
176 on the complementary strand exhibited a high density of G>A transitions (Fig 2C and S8 Fig). Additionally,
177 sperm and blood cells from M0038 exhibited no significant difference in the patterns of postzygotic
178 mutations in the 96 mutation contexts and the mutational strand asymmetries (Fig 2A and S6 – S8 Figs).
179 Both tissues had higher levels of C>T transition at GpCpN than at NpCpG, indicating the same mutational
180 processes. In brief, consistent VAF of mutations in samples of time series, similar proportions of C>T at
181 GpCpN across samples from different individuals, and evidence of mutational strand asymmetries gave
182 support to the reliability of mutation profiles we observed.

183

184 **A mutational signature characterized by C>T at GpCpN commonly occurred in normal blood cells**

185 To explore the whether these mutation patterns were also represented in other normal tissues, we collected
186 deep exome sequencing datasets (>200×) for one muscle sample from individual M0038 and normal blood
187 cell samples paired to tumor samples in three types of tumors, including esophageal squamous cell carcinoma
188 (ESCC), acute myelocytic leukemia (AML), and chordoma (Fig 3A). In addition, targeted sequencing data
189 for normal skin and single cell sequencing data for neurons were also analyzed (Fig 3A). The most significant
190 mutation feature observed in normal blood cells in these tumor studies was the enrichment of C>T transitions
191 at GpCpN sites, especially the GpCpC trinucleotide, consistent with above profiles in healthy individuals.
192 This kind of enrichment was also observed in the solid tissues, especially in neuron and muscle. Besides, all
193 paired tumor samples did not have this feature detected in their mutation profiles. These strongly suggests
194 that C>T at GpCpN sites commonly occurs in normal cells.

195 **Fig. 3. C>T at GpCpN sites in normal and tumor cells.** (A) Heat map of mutation proportions illustrates the enrichment of
196 C>T at GpCpN in all types of normal cell (black) in both healthy subjects (upper) and patients (lower). With the exception of
197 enrichment of C>T at GpCpC in a portion of CCRCC, no specific mutation preference was identified in the trinucleotide
198 contexts of various cancer cells (blue, note: data of AML sequencing are presented only for normal T lymphocytes, but not
199 leukemic cells). However, distinct enrichment of C>T at GpCpN was demonstrated in all normal cells from both healthy

individuals (upper 4) and paired blood samples in tumor patients (black in lower part). The mutation data presented from top to bottom are derived from the following sources: six blood samples of healthy individuals in this study; three sperm samples of subject M0038; one muscle sample of subject M0038 (>200×, VAF = 0.021±0.015); targeted sequencing (>500×, VAF = 0.042±0.048) of 74 genes in 234 skin samples from four individuals as reported by Martincorena *et al.* [5]; whole-genome sequencing of 36 single neurons of three individuals as reported by Lodato *et al.* [26]; in-house exome sequencing of 23 ESCC tumors and paired blood samples (both >200×, VAF = 0.017±0.009 in paired blood samples, VAF = 0.175±0.136 in tumors); in-house exome sequencing of two chordoma tumors and paired blood samples (both >250×, VAF = 0.017±0.005 in paired blood samples, VAF = 0.295±0.200 in tumors); in-house exome sequencing (>200×, VAF = 0.019±0.008) of 11 samples of normal T lymphocytes that were paired with AML cells (data not shown); exome sequencing of 295 CCRCC from TCGA; and those CCRCC with a high rate of C>T transition at GpCpC sites among the 295 samples. (B) A mutational signature revealed by non-negative matrix factorization in all 56 normal cell samples. Signature A involves spontaneous deamination of 5mC at NpCpG, Signature B features C>T and T>C transitions and Signature C features a mutational type characterized as C>T at GpCpN sites. (C) Varying proportions of the three signatures in 56 normal samples. Signature C contributed to at least 10% of the mutations in all samples and was the major mutational type in ~30 samples. (D) With the proportion of Signature B as the quantitative value, 125 SNPs located in 54 genes correlated with the proportion of signatures by whole-exome association analysis (permutation test, $p < 1\times10^{-10}$).

Next, we merged deep exome sequencing datasets of all 56 normal tissue samples (Fig 3A, Methods), and resolved Three mutational signatures, A, B and C (Fig 3B). Signature A is known to be associated with the spontaneous deamination of methylated cytosine to thymine at NpCpG [7, 11, 27], and Signature B is known to be clock-like that the number of mutations in cancers and normal cells correlates with the age of the individual. In addition to these two known signatures, we revealed a Signature C characterized by C>T transitions at GpCpN trinucleotides, especially GpCpC sites. In particular, Signature C was found to be the major contributor to somatic mutations detected in more than 30 normal samples (Fig 3C).

Epigenetic regulation may influence the proportion of mutational signatures in normal tissues

To identify genetic factors contributing to these mutational processes, we further performed whole-exome association analysis with age as a covariate and the frequency of Signature A, B and C as the quantitative value respectively, in our 40 unrelated normal samples (Methods). In total, 21 SNPs located in 18 protein coding genes were shown to correlate with the proportions of Signature B ($p < 1\times10^{-10}$, permutation test;

229 Fig 3D and Table 1). Among these, 2 genes contained SET domain (enrichment P=0.031), which is an
230 important sequence feature of putative methyl transferase involved in histone methylation. The 2 genes are
231 *PRDM9* (PR Domain 9), a zinc finger protein catalyzes the trimethylation of histone H3 lysine 4 (H3K4me3)
232 and *KMT2C*, a histone methyltransferase involve in leukemogenesis and developmental disorder [28-30].
233 This result indicates mutations in epigenetic regulators may influence the proportion of signature B in normal
234 tissue. Moreover, two SNPs in *NOTCH2* are associated with the proportion of Signature B and C,
235 respectively (Table 1). *NOTCH2* is a key member of notch signaling pathway, which is important in
236 metazoan development and tissue renewal. Its inter-cellular domain can act as a transcription factor regulates
237 cell proliferation through controlling the expression of cycling D1[31, 32] . Additionally, there is no SNPs
238 were significant associated with Signature A. These results demonstrate genetic background may influence
239 the mutational profile of each individual.

240 **Table 1.** Genes revealed by association analysis of signature frequency with whole-exome sequencing

CHR	POS[a]	BETA[b]	STAT[c]	P	Adjust P[d]	GENE
Signature B						
1	120,539,668	0.41	9.17	4.61×10^{-11}	6.55×10^{-8}	*NOTCH2*
5	23,527,777	0.64	9.21	4.13×10^{-11}	1.26×10^{-7}	*PRDM9*
7	151,945,204	0.55	9.39	2.51×10^{-11}	8.48×10^{-8}	*KMT2C*
7	151,962,309	0.43	9.60	1.40×10^{-11}	6.55×10^{-8}	*KMT2C*
9	33,386,243	-0.81	-10.36	1.75×10^{-12}	1.77×10^{-8}	*AQP7*
9	33,798,543	0.67	10.47	1.28×10^{-12}	1.77×10^{-8}	*PRSS3*
12	53,865,349	0.63	9.07	6.21×10^{-11}	1.40×10^{-7}	*PCBP2*
12	111,885,367	0.64	9.31	3.09×10^{-11}	9.90×10^{-8}	*SH2B3*
13	20,247,238	-0.67	-10.47	1.28×10^{-12}	1.77×10^{-8}	*MPHOSPH8*
13	25,671,429	1.11	9.09	5.79×10^{-11}	1.36×10^{-7}	*PABPC3*
16	33,410,688	0.55	9.39	2.51×10^{-11}	8.48×10^{-8}	-
17	21,319,682	-0.67	-10.93	3.87×10^{-13}	1.77×10^{-8}	*KCNJ12*
17	44,850,996	1.11	9.09	5.79×10^{-11}	1.36×10^{-7}	*WNT3*
17	45,214,558	-0.67	-10.47	1.28×10^{-12}	1.77×10^{-8}	*CDC27*
19	3,586,698	0.63	9.05	6.51×10^{-11}	1.41×10^{-7}	*GIPC3*
19	9,012,789	0.63	9.10	5.66×10^{-11}	1.36×10^{-7}	*MUC16*
19	17,734,390	1.11	9.09	5.79×10^{-11}	1.36×10^{-7}	*UNC13A*
20	26,094,525	1.11	9.09	5.79×10^{-11}	1.36×10^{-7}	*NCOR1P1*
20	29,625,935	0.55	9.39	2.51×10^{-11}	8.48×10^{-8}	*FRG1BP*
21	11,058,227	0.55	9.39	2.51×10^{-11}	8.48×10^{-8}	*BAGE5*
21	11,058,229	0.55	9.39	2.51×10^{-11}	8.48×10^{-8}	*BAGE5*

Signature C						
1	120,539,687	-0.42	-9.04	6.59×10^{-11}	2.07×10^{-6}	*NOTCH2*

a. Human reference genome build GRCh37.

b. Regression coefficient.

c. Coefficient *t*-statistic.

d. Adjusted p-value was calculated by Benjamini & Hochberg (1995) step-up FDR control.

Signature C was a development associated mutational type

Among all three mutational types identified above, Signature A and B have been reported to associate with age related process. However, such an age-related accumulation was not seen in our time point samples, i.e., sperm and blood, perhaps because of their liquid feature. Sequencing of liquid samples are likely to capture mutants in a large cell population with relatively high VAFs which may reflect their early occurrence during embryo development. In contrast, a solid tissue is maintained or regenerated by limited stem cells in a local region. Therefore, the late stage mutations mingled with early ones may be distinguished in sequencing data by VAF. As expected, mutations in muscle biopsy samples had significantly higher VAFs than those in blood and sperm samples (Fig 1C, $P < 2.2\times10^{-16}$). We then divided muscle mutations into high VAF group, which was more likely generated during embryo development, and low VAF group with the cutoff of VAF = 0.025. In high VAF group, a significantly high proportion of C>T at GpCpC sites, the Signature C, was observed (0.185 vs 0.06, S9 Fig), suggesting the association of this mutation type with the development.

Hypoxia contributed to the occurrence of Signature C

We extracted sequencing datasets from The Cancer Genome Atlas (TCGA, Methods), including 3,827 samples from 22 types of tumor (S10 Fig) [2, 11, 33]. For the somatic mutation profiles, only a small proportion of TCGA tumor samples (4%, 153/3,827) exhibited high numbers of C>T transitions in the GpCpC context, of which 58 were clear cell renal cell carcinoma (CCRCC, S4 Table). Notably, they were distinguished from the rest of the 273 CCRCC samples in cluster analysis (Fig 4A) and their similarity to various types of normal tissue indicated that the same mutational processes occurred in both CCRCC and normal cells.

266 By comparing the expression profiles of high- (58 samples) and low-GpCpC groups (the remaining 237
267 samples) of CCRCC, we resolved 145 differentially expressed genes ($p < 0.05$, chi-squared test; Fig 4B,
268 Methods). The most significant change in the high-GpCpC group was the increased transcription of
269 PPP1R12A (protein phosphatase 1 regulatory subunit 12A), which activates hypoxia-inducible factor (HIF)-
270 1α [34] (adjust-p = 8.82×10^{-5}, Benjamini-Hochberg method, Fig 4C). Moreover, the Hippo pathway was
271 significantly enriched ($p = 3.21\times10^{-5}$), which is associated with the transcriptional response to hypoxia [35-
272 37]. Additionally, a slightly higher mutation rate of VHL (0.5 vs 0.43), whose product is involved in the
273 ubiquitination and degradation of HIF proteins [38], was also observed in the high-GpCpC group (S5 Table).
274 Taken together, these results suggest that increased activity of the HIF signaling pathway may contribute to
275 the high proportion of C>T transitions at GpCpC in these CCRCC samples.

276 **Fig. 4. High GpCpC mutations in parts of CCRCC.** (A) Correlation matrix of normal (black) and tumor (blue) cells. Among
277 all tumors, a group of 58 CCRCC samples with high C>T transition at GpCpC were similar to normal cells regarding the
278 mutational patterns. (B) Differentially expressed genes of CCRCC with high (left) and low GpCpC (right) after comparison
279 with their adjacent normal tissues in TCGA. A total of 145 up- (red) and downregulated genes (yellow) were identified between
280 the two groups. (C) Among the significantly differentially expressed genes ($p < 0.01$) in the high-GpCpC group, the top one
281 *PPP1R12A* ($p = 8.82\times10^{-5}$) activates *HIF1A* by inhibiting HIF1AN-dependent suppression [34].

282 To test the roles of the HIF signaling pathway, we treated the human embryonic stem cell (hESC) line WA07
283 (WiCell Research Institute) with ML228, a direct activator of the HIF signaling pathway, through stabilizing
284 and activating the nuclear translocation of HIF-1α [39] (Methods, Fig 5A). In the first stage, WA07 cells
285 were divided into two groups with ~1,000 cells in each. One group was treated with ML228 (0.125 nmol/ml)
286 for 15 days, and the other was treated with mock as a control. For the second stage, 10 cells were randomly
287 picked up from each group and expanded to ~1,000 cells with or without ML228, before harvesting for
288 exome sequencing with barcoding in library construction (Methods). As expected, a significantly high
289 proportion of C>T transitions at GpCpN was observed in ML228-treated cells in comparison with the level
290 in the control (0.17 vs. 0.07, $p = 0.0091$, chi-squared test; Fig 5B–C). According to their proportions, we
291 divided all detected mutants into high- (VAF>0.05, mainly originating in the first stage) and low-allele-
292 fraction mutations (VAF≤0.05, mainly generated from the expansion process in the second stage). For both
293 types of mutation, higher accumulation of C>T transitions at GpCpN was observed in treated cells than in
294 the control (0.12 vs. 0.06 in the high allele fraction and 0.20 vs. 0.08 in the low allele fraction; S11 Fig).

295 These results demonstrate that activation of the HIF signaling pathway can lead to C>T transitions at GpCpN.

296 **Fig. 5. Activation of the HIF pathway by ML228 led to a high proportion of C>T transitions in the GpCpN context in**
297 **hESC cells.** (A) Two-stage treatment of WA07 cells with ML228 followed by exome sequencing with molecular barcoding.
298 (B) A higher proportion of C>T transitions in the GpCpN context in ML228-treated cells. Note that the C>T transitions
299 constituted the most significant difference in the GpCpC context of the ML228 group (0.07 vs. 0.01). (C) The fluctuation of
300 96 mutation types upon two-stage ML228 treatment. Among the 40 increased (red) and 26 decreased (blue) mutation types,
301 C>T in the CpGpN context contributed to 14% of the total fluctuations, and half of this contribution was caused by the
302 accumulation of C>T at GpGpC.

303

304 # Discussion

305 In this study, based on postzygotic mutation profiles in healthy individuals from five trio families, we
306 discovered a signature characterized by C>T transitions in GpCpN trinucleotides as a major mutation type
307 shared by blood and sperm cells. A solid evidence for this mutational pattern as a hallmark trait of normal
308 tissues came from our observations in public or collaborative datasets eligible for analysis that such a
309 signature was observed in all normal tissues but only very limited cancers. Furthermore, a portion of CCRCC
310 with higher expression of HIF related pathways were featured by this mutation type, which lead to our
311 speculation that the hypoxia status may trigger such mutations in healthy people. To prove this proposal, we
312 designed an in vitro experiment using human embryo stem cell and we indeed observed accumulation of
313 C>T transitions in GpCpN trinucleotides upon hypoxia induction.

314 Patterns of low VAF mutations in cell populations may be confounded by sequencing errors, and most
315 sequencing artifacts are due to DNA damage during extraction and acoustic shearing [40, 41]. We used
316 several strategies to assure the mutation authenticity. First, we largely reduced DNA damage before
317 sequencing by introduction of repair mix ($p < 0.05$, S12 Fig, see Methods). We also used an optimized variant
318 calling method to mask sequencing noise which allowed us to produce high-confidence calls of postzygotic
319 mutations with VAF around 0.005 (See postzygotic mutation detection in Methods). Another challenge to
320 identify postzygotic mutations is that under certain situations, it is difficult to distinguish inherited variants
321 from postzygotic mutations due to inaccurate allele fractions in NGS sequencing. The theoretical values for
322 allele fraction of inherited heterozygous variations should be 0.5, however measured values usually range

323 from 0.2 to 0.6 due to unequal sequencing coverage of both alleles [42]. Actually, in our trio families,
324 inherited mutations may have allele fractions even around 0.1 to 0.3 in the sequencing data from siblings
325 (S13 Fig). Therefore, in addition to the filtering algorithms [43], we applied trio-based sequencing to
326 preclude inherited mutations, and in this way common sequencing errors in multiple individuals can also be
327 removed at the mean time. Validation of called variants with multiple methods ensured the confidence of our
328 observation (S3 Table). Most importantly, in human embryo stem cells, we successfully generated our newly
329 identified mutational signature by introduction of mutagenesis (Fig 5), which greatly supported the reliability
330 of our findings.

331 To trace the mutagenesis process responsible for the signature, tumor samples in TCGA database provide us
332 an interesting clue that this signature specific to normal tissues can be only found in a portion of CCRCC,
333 known to be associated with activation of the HIF pathway [44]. Moreover, in recurrent glioblastoma,
334 featured by extremely hypoxic conditions in tumor microenvironment [45], a recent study showed that C>T
335 at GpCpC and GpCpT were enriched in their mutation spectrums (S2 Appendix and S14 Fig) [46].
336 Meanwhile, paired transcriptome analysis for the high-GpCpC group of CCRCC demonstrated that their HIF
337 pathway was more active than that in the low-GpCpC group (Fig 4). The induction of GpCpC mutation by
338 HIF signaling pathway was further validated in oligoclonal culture of hESCs. By directly activation of HIF1-
339 α in oligoclonal hESCs using ML228, a previous well established assay [39], and a specially designed two-
340 step cell culture experiments (Fig 5), we successfully observed the significant accumulation of C>T at
341 GpCpN in mutational profiles.

342 In particular, we observed the same signatures for mutations in the blood and sperm tissues, indicating their
343 common mutagenesis process. In fact, such C>T at GpCpC sites could also be seen in mutation profile of
344 normal blood samples from a newborn baby study [47] . Notably, our samples carried high proportion of
345 mutations in the range of 0.01~0.05. This range of mutation fractions infer their occurrence within 20 cell
346 divisions after fertilization. In view of HIF pathway being crucial in oxygen-sensing to mediate tissue
347 adaptation to hypoxia, and hypoxic condition as a critical feature during embryonic development [48], we
348 believe that the C>T transitions at GpCpN sites may occur during the embryonic development under the
349 hypoxia status [49, 50]. In addition to our experimental validation with human stem cells, GpCpN mutations
350 can also be observed in normal neurons, in which the accumulation of C>T at GpCpN mutations were

351 significantly higher than those caused by deamination of methylated cytosines in NpCpG sites (Fig 3A, S2
352 Appendix, and S15 Fig, p=0.047, t-test) [26]. Since neuron cell division stops after the neuroepithelial cells
353 have differentiated into proper neurons; most mutations should occur during cortical neurogenesis, which is
354 complete around week 15 post-conception [51].

355 It is the two unique features in our sequencing strategy, the utilization of liquid samples sperm and blood,
356 and the bulk sequencing without further separation or cloning, that allowed us to be able to capture those of
357 relative common mutations in each tissue that occurred in the early stage of a cell lineage. In contrast,
358 previous studies on postzygotic mutations mainly focusing on cancer somatic mutations, organoid mutations,
359 or *de novo* mutations [1, 5, 52], most of which are private genomic changes in certain cell lineages across
360 all the life span. In these mutation spectra, therefore, early events only account for a small proportion and
361 possibly overwhelmed by all other mutations. This also explains why we observed the same signatures for
362 mutations in the blood and sperm tissues, indicating their common mutagenesis process most likely during
363 embryonic development.

364 Finally, integrating previously reported *de novo* mutations (S16 Fig), somatic mutations in CCRCC, and our
365 results, we illustrate a mutational signature and corresponding active mutational processes during embryonic
366 and post-parturition development, as well as in tumor development (Fig 6). Across the individuals' lifespan,
367 C>T transitions at NpCpG trinucleotides due to spontaneous deamination constantly occur after fertilization.
368 In embryo development, the hypoxic environment triggers the occurrence and accumulation of C>T at
369 GpCpN sites. After birth, T>C transition was generated in normal cells based on *de novo* mutations. In
370 CCRCC, all types of mutation process were present. All of the aforementioned mutational processes can be
371 observed in all tissue types. In future investigations, samples of multiple normal tissues from one individual
372 should help to validate the molecular mechanism of hypoxia condition in mutation accumulation during
373 embryonic development.

374 **Fig. 6. Proposed mutational processes (bottom) over the lifespan (top left) and in cancer of CCRCC (top right).** After
375 fertilization, the spontaneous deamination of methylated cytosine at NpCpG is the most common mutation type associated
376 with age. In the early stage of embryonic development characterized by hypoxia, C>T transitions commonly occur at GpCpN
377 sites. The enrichments of T>C transitions with unknown etiology are other mutational processes that occur during development.
378 Regarding CCRCC development, the hypoxia-induced mutation process causes C>T transitions at GpCpN sites. Other
379 mutational patterns in CCRCC include errors in mismatch repair and T>A transversions via unknown mechanisms. The dashed

380 lines represent a lack of supporting evidence in a given stage.

381

382 # Materials and Methods

383 More detailed information is provided in S1 Appendix.

384 ## Samples and whole exome sequencing

385 Individuals F0061, M0070, M0072, M0074, and their parents were enrolled at Wenzhou Medical University
386 and samples from M0038 and his parents were collected at Beijing Institute of Genomics, Chinese Academy
387 of Sciences (CAS). The five samples were 5-33 years of age and included four males and one female (S1
388 Table). All the details of whole exome sequencing analysis are summarized in S1 Appendix. This study was
389 approved by the ethics committees of both Beijing Institute of Genomics, CAS (NO. 2016H006) and the Eye
390 Hospital of Wenzhou Medical University (NO. KYK [2015] 2), and it was conducted in accordance with the
391 principles of the Declaration of Helsinki principles. All the participants were healthy and provided written
392 informed consent.

393 ## Postzygotic mutation detection

394 Based on the error estimation model (detailed information is provided in S1 Appendix), postzygotic
395 mutations in normal cells were detected by following several steps. Sequencing reads were aligned to the
396 human reference genome build GRCh37 using the BWA algorithm [53] after the removal of adapter segments
397 and the exclusion of reads with low Q-scores (S1 Appendix). Uniquely mapped reads with less than 3
398 mismatched bases were then processed using the error estimation model for all target regions, and variants
399 with $P^m > P^\varepsilon$ were selected out. Then, variants with more than 1% of reads supporting an alternative allele
400 in either of the parents were removed to filter the inherited variants. In addition, due to the potential for
401 misalignment, we only kept the variants included in the strict mask regions of the 1000 Genomes Project
402 phase 1 [54].

403 ## Mutational signature analysis

404 Mutational signatures were analyzed based on the guidelines of the Wellcome Trust Sanger Institute [11, 27].
405 The percentages of the 96 possible mutated trinucleotides in each sample, which were identified according

406 to the six classes of base substitutions and 16 sequence contexts immediately 5' and 3' to the mutated base,
407 were firstly calculated. The contexts of all mutations were extracted from the human reference genome build
408 GRCh37. The mutational signatures in the selected samples were then estimated using the nonnegative
409 matrix factorization (NMF) learning strategy. An appropriate number of mutational signatures was identified
410 by calculating the reproducibility value and reconstruction error for all samples. Each mutational signature
411 was finally displayed with the proportions of the 96 trinucleotides, and its contribution to each sample was
412 estimated.

413 **Cell culture and molecular barcoded whole exome sequencing**

414 The WA07 (WiCell Research Institute) cells were divided into two groups with ~1,000 cells each and
415 maintained in the human pluripotent stem cell chemical-defined medium (hPSC-CDM^{TM}, Baishou
416 Biotechnology Co. LTD) according to the protocol. One group was treated with ML228 at 0.125 nmol/ml
417 and the other group was treated with mock as the control. Both two groups were cultured for 15 day and
418 cells received fresh medium with/without ML228 every other day. Then ~10 cells were randomly selected
419 from each group and cultured in the aforementioned medium with/without ML228 (0.125 nmol/ml),
420 respectively. Cells received fresh medium with/without ML228 every five days. Molecular barcoded whole
421 exome sequencing was performed on each group of cells after expanded to ~1,000 cells. Genomic DNA of
422 cultured expanded WA07 cells were extracted with a QIAamp DNA Mini Kit (Qiagen), per the
423 manufacturer's protocols. Partition barcoded libraries were then prepared based on the Chromium Exome
424 Solution (10X Genomics) and the exome target regions was enriched by SureSelect Human All Exon V5 Kit
425 (Agilent) according to the protocols. The target-enriched libraries with molecular barcoding were
426 subsequently sequenced on a HiSeq 4000 (Illumina) with 150-bp paired-end reads.

427 **Mutation detection in hESCs**

428 The exome sequencing data with molecular barcodes of WA07 cells was analyzed with the Long Ranger
429 (10X Genomics). Then, the mutations which contained multiple molecular barcodes in the mismatched reads
430 were kept. And to reduce the false positive rate, we removed the mutations which contained both two allele
431 types in one molecular barcode in the site.

432 **Availability of data and materials**

All sequencing data generated during the current study are available in the Genome Sequence Archive (http://gsa.big.ac.cn) with the accession number of CRA000071. Sources of the public tumor data used in this study are provided in the S1 Appendix.

Acknowledgments

The authors gratefully thank Dr. Ian M. Campbell and Dr. Pawel Stankiewicz from Baylor College of Medicine for kindly providing R source code for building cell-division model. The authors thank Dr. Xinyu Zhang from Yale University for critical reading and comments on the manuscript. The authors also thank Dr. Caixia Guo from Beijing Institute of Genomics, CAS for interpreting possible mechanisms underlying the occurrence of postzygotic mutations.

References

1. Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Al Turki S, et al. Timing, rates and spectra of human germline mutation. Nat Genet. 2016;48(2):126-33. doi: 10.1038/ng.3469. PubMed PMID: 26656846; PubMed Central PMCID: PMC4731925.

2. Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S, et al. Clock-like mutational processes in human somatic cells. Nat Genet. 2015;47(12):1402-7. Epub 2015/11/10. doi: 10.1038/ng.3441. PubMed PMID: 26551669; PubMed Central PMCID: PMC4783858.

3. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366-74. doi: 10.1038/35077232. PubMed PMID: 11357144.

4. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458(7239):719-24. doi: 10.1038/nature07943. PubMed PMID: 19360079; PubMed Central PMCID: PMC2821689.

5. Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science. 2015;348(6237):880-6. doi: 10.1126/science.aaa6806. PubMed PMID: 25999502; PubMed Central PMCID: PMC4471149.

6. Brunner SF, Roberts ND, Wylie LA, Moore L, Aitken SJ, Davies SE, et al. Somatic mutations and clonal dynamics in healthy and cirrhotic human liver. Nature. 2019;574(7779):538-42. Epub 2019/10/28. doi: 10.1038/s41586-019-1670-9. PubMed PMID: 31645727; PubMed Central PMCID: PMC6837891.

7. Helleday T, Eshtad S, Nik-Zainal S. Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet. 2014;15(9):585-98. doi: 10.1038/nrg3729. PubMed PMID: 24981601.

461 8. Hart JR, Zhang Y, Liao L, Ueno L, Du L, Jonkers M, et al. The butterfly effect in cancer: A single base
462 mutation can remodel the cell. Proc Natl Acad Sci U S A. 2015;112(4):1131-6. doi: 10.1073/pnas.1424012112.
463 PubMed PMID: 25583473; PubMed Central PMCID: PMC4313835.
464 9. Blokzijl F, de Ligt J, Jager M, Sasselli V, Roerink S, Sasaki N, et al. Tissue-specific mutation accumulation
465 in human adult stem cells during life. Nature. 2016;538(7624):260-4. doi: 10.1038/nature19768. PubMed PMID:
466 27698416.
467 10. Martincorena I, Fowler JC, Wabik A, Lawson ARJ, Abascal F, Hall MWJ, et al. Somatic mutant clones
468 colonize the human esophagus with age. Science. 2018. Epub 2018/10/20. doi: 10.1126/science.aau3879. PubMed
469 PMID: 30337457.
470 11. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of
471 mutational processes in human cancer. Nature. 2013;500(7463):415-21. doi: 10.1038/nature12477. PubMed
472 PMID: 23945592; PubMed Central PMCID: PMC3776390.
473 12. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. Deciphering signatures of mutational
474 processes operative in human cancer. Cell Rep. 2013;3(1):246-59. Epub 2013/01/16. doi:
475 10.1016/j.celrep.2012.12.008. PubMed PMID: 23318258; PubMed Central PMCID: PMC3588146.
476 13. Lee DD, Seung HS. Learning the parts of objects by non-negative matrix factorization. Nature.
477 1999;401(6755):788-91. doi: 10.1038/44565. PubMed PMID: 10548103.
478 14. Alexandrov LB, Ju YS, Haase K, Van Loo P, Martincorena I, Nik-Zainal S, et al. Mutational signatures
479 associated with tobacco smoking in human cancer. Science. 2016;354(6312):618-22. doi:
480 10.1126/science.aag0299. PubMed PMID: 27811275.
481 15. Kong A, Frigge ML, Masson G, Besenbacher S, Sulem P, Magnusson G, et al. Rate of de novo mutations
482 and the importance of father's age to disease risk. Nature. 2012;488(7412):471-5. Epub 2012/08/24. doi:
483 10.1038/nature11396. PubMed PMID: 22914163; PubMed Central PMCID: PMC3548427.
484 16. Cai J, Miao X, Li Y, Smith C, Tsang K, Cheng L, et al. Whole-genome sequencing identifies genetic variances
485 in culture-expanded human mesenchymal stem cells. Stem Cell Reports. 2014;3(2):227-33. doi:
486 10.1016/j.stemcr.2014.05.019. PubMed PMID: 25254336; PubMed Central PMCID: PMC4176531.
487 17. Krimmel JD, Schmitt MW, Harrell MI, Agnew KJ, Kennedy SR, Emond MJ, et al. Ultra-deep sequencing
488 detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues. Proc
489 Natl Acad Sci U S A. 2016;113(21):6005-10. doi: 10.1073/pnas.1601311113. PubMed PMID: 27152024; PubMed
490 Central PMCID: PMC4889384.

491 18. Hoang ML, Kinde I, Tomasetti C, McMahon KW, Rosenquist TA, Grollman AP, et al. Genome-wide
492 quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. Proc Natl
493 Acad Sci U S A. 2016;113(35):9846-51. doi: 10.1073/pnas.1607794113. PubMed PMID: 27528664; PubMed
494 Central PMCID: PMC5024639.
495 19. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-
496 cell sequencing. Nature. 2011;472(7341):90-4. doi: 10.1038/nature09807. PubMed PMID: 21399628; PubMed
497 Central PMCID: PMC4504184.
498 20. Forsberg LA, Gisselsson D, Dumanski JP. Mosaicism in health and disease - clones picking up speed. Nat
499 Rev Genet. 2017;18(2):128-42. doi: 10.1038/nrg.2016.145. PubMed PMID: 27941868.
500 21. Lee-Six H, Olafsson S, Ellis P, Osborne RJ, Sanders MA, Moore L, et al. The landscape of somatic mutation
501 in normal colorectal epithelial cells. Nature. 2019;574(7779):532-7. Epub 2019/10/28. doi: 10.1038/s41586-019-
502 1672-7. PubMed PMID: 31645730.
503 22. Behjati S, Huch M, van Boxtel R, Karthaus W, Wedge DC, Tamuri AU, et al. Genome sequencing of normal
504 cells reveals developmental lineages and mutational processes. Nature. 2014;513(7518):422-5. doi:
505 10.1038/nature13448. PubMed PMID: 25043003.
506 23. Campbell IM, Yuan B, Robberecht C, Pfundt R, Szafranski P, McEntagart ME, et al. Parental somatic
507 mosaicism is underrecognized and influences recurrence risk of genomic disorders. Am J Hum Genet.
508 2014;95(2):173-82. doi: 10.1016/j.ajhg.2014.07.003. PubMed PMID: 25087610; PubMed Central PMCID:
509 PMC4129404.
510 24. Campbell IM, Stewart JR, James RA, Lupski JR, Stankiewicz P, Olofsson P, et al. Parent of origin, mosaicism,
511 and recurrence risk: probabilistic modeling explains the broken symmetry of transmission genetics. Am J Hum
512 Genet. 2014;95(4):345-59. Epub 2014/09/23. doi: 10.1016/j.ajhg.2014.08.010. PubMed PMID: 25242496;
513 PubMed Central PMCID: PMC4185125.
514 25. Gao JJ, Pan XR, Hu J, Ma L, Wu JM, Shao YL, et al. Highly variable recessive lethal or nearly lethal mutation
515 rates during germ-line development of male Drosophila melanogaster. Proc Natl Acad Sci U S A.
516 2011;108(38):15914-9. Epub 2011/09/06. doi: 10.1073/pnas.1100233108. PubMed PMID: 21890796; PubMed
517 Central PMCID: PMC3179084.
518 26. Lodato MA, Woodworth MB, Lee S, Evrony GD, Mehta BK, Karger A, et al. Somatic mutation in single
519 human neurons tracks developmental and transcriptional history. Science. 2015;350(6256):94-8. doi:
520 10.1126/science.aab1785. PubMed PMID: 26430121; PubMed Central PMCID: PMC4664477.

521 27. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, et al. Mutational processes
522 molding the genomes of 21 breast cancers. Cell. 2012;149(5):979-93. doi: 10.1016/j.cell.2012.04.024. PubMed
523 PMID: 22608084; PubMed Central PMCID: PMC3414841.
524 28. Eram MS, Bustos SP, Lima-Fernandes E, Siarheyeva A, Senisterra G, Hajian T, et al. Trimethylation of
525 histone H3 lysine 36 by human methyltransferase PRDM9 protein. J Biol Chem. 2014;289(17):12177-88. doi:
526 10.1074/jbc.M113.523183. PubMed PMID: 24634223; PubMed Central PMCID: PMC4002121.
527 29. Davies B, Hatton E, Altemose N, Hussin JG, Pratto F, Zhang G, et al. Re-engineering the zinc fingers of
528 PRDM9 reverses hybrid sterility in mice. Nature. 2016;530(7589):171-6. doi: 10.1038/nature16931. PubMed
529 PMID: 26840484; PubMed Central PMCID: PMC4756437.
530 30. Lee S, Lee DK, Dou Y, Lee J, Lee B, Kwak E, et al. Coactivator as a target gene specificity determinant for
531 histone H3 lysine 4 methyltransferases. Proc Natl Acad Sci U S A. 2006;103(42):15392-7. Epub 2006/10/06. doi:
532 10.1073/pnas.0607313103. PubMed PMID: 17021013; PubMed Central PMCID: PMC1622834.
533 31. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell.
534 2009;137(2):216-33. Epub 2009/04/22. doi: 10.1016/j.cell.2009.03.045. PubMed PMID: 19379690; PubMed
535 Central PMCID: PMC2827930.
536 32. Das D, Lanner F, Main H, Andersson ER, Bergmann O, Sahlgren C, et al. Notch induces cyclin-D1-
537 dependent proliferation during a specific temporal window of neural differentiation in ES cells. Dev Biol.
538 2010;348(2):153-66. Epub 2010/10/05. doi: 10.1016/j.ydbio.2010.09.018. PubMed PMID: 20887720.
539 33. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the
540 world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43(Database issue):D805-11.
541 doi: 10.1093/nar/gku1075. PubMed PMID: 25355519; PubMed Central PMCID: PMC4383913.
542 34. Webb JD, Muranyi A, Pugh CW, Ratcliffe PJ, Coleman ML. MYPT1, the targeting subunit of smooth-muscle
543 myosin phosphatase, is a substrate for the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor
544 (FIH). Biochem J. 2009;420(2):327-33. doi: 10.1042/BJ20081905. PubMed PMID: 19245366.
545 35. Saucedo LJ, Edgar BA. Filling out the Hippo pathway. Nat Rev Mol Cell Biol. 2007;8(8):613-21. doi:
546 10.1038/nrm2221. PubMed PMID: 17622252.
547 36. Pan D. The hippo signaling pathway in development and cancer. Dev Cell. 2010;19(4):491-505. doi:
548 10.1016/j.devcel.2010.09.011. PubMed PMID: 20951342; PubMed Central PMCID: PMC3124840.
549 37. Ma B, Chen Y, Chen L, Cheng H, Mu C, Li J, et al. Hypoxia regulates Hippo signalling through the SIAH2
550 ubiquitin E3 ligase. Nat Cell Biol. 2015;17(1):95-103. doi: 10.1038/ncb3073. PubMed PMID: 25438054.

551 38. Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15(1):55-
552 64. doi: 10.1038/nrc3844. PubMed PMID: 25533676.
553 39. Theriault JR, Felts AS, Bates BS, Perez JR, Palmer M, Gilbert SR, et al. Discovery of a new molecular probe
554 ML228: an activator of the hypoxia inducible factor (HIF) pathway. Bioorg Med Chem Lett. 2012;22(1):76-81.
555 Epub 2011/12/17. doi: 10.1016/j.bmcl.2011.11.077. PubMed PMID: 22172704; PubMed Central PMCID:
556 PMC3251333.
557 40. Chen L, Liu P, Evans TC, Jr., Ettwiller LM. DNA damage is a pervasive cause of sequencing errors, directly
558 confounding variant identification. Science. 2017;355(6326):752-6. doi: 10.1126/science.aai8690. PubMed PMID:
559 28209900.
560 41. Costello M, Pugh TJ, Fennell TJ, Stewart C, Lichtenstein L, Meldrim JC, et al. Discovery and
561 characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA
562 damage during sample preparation. Nucleic Acids Res. 2013;41(6):e67. Epub 2013/01/11. doi:
563 10.1093/nar/gks1443. PubMed PMID: 23303777; PubMed Central PMCID: PMC3616734.
564 42. Acuna-Hidalgo R, Bo T, Kwint MP, van de Vorst M, Pinelli M, Veltman JA, et al. Post-zygotic point
565 mutations are an underrecognized source of se novo genomic variation. Am J Hum Genet. 2015;97(1):67-74. Epub
566 2015/06/10. doi: 10.1016/j.ajhg.2015.05.008. PubMed PMID: 26054435; PubMed Central PMCID:
567 PMC4571017.
568 43. Salk JJ, Schmitt MW, Loeb LA. Enhancing the accuracy of next-generation sequencing for detecting rare
569 and subclonal mutations. Nat Rev Genet. 2018;19(5):269-85. Epub 2018/03/27. doi: 10.1038/nrg.2017.117.
570 PubMed PMID: 29576615.
571 44. Seton-Rogers S. Hypoxia: New connections. Nat Rev Cancer. 2012;12(5):320. Epub 2012/04/13. doi:
572 10.1038/nrc3267. PubMed PMID: 22495320.
573 45. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxia-inducible factors regulate
574 tumorigenic capacity of glioma stem cells. Cancer Cell. 2009;15(6):501-13. doi: 10.1016/j.ccr.2009.03.018.
575 PubMed PMID: 19477429; PubMed Central PMCID: PMC2693960.
576 46. Wang J, Cazzato E, Ladewig E, Frattini V, Rosenbloom DI, Zairis S, et al. Clonal evolution of glioblastoma
577 under therapy. Nat Genet. 2016;48(7):768-76. doi: 10.1038/ng.3590. PubMed PMID: 27270107.
578 47. Zhang L, Dong X, Lee M, Maslov AY, Wang T, Vijg J. Single-cell whole-genome sequencing reveals the
579 functional landscape of somatic mutations in B lymphocytes across the human lifespan. Proc Natl Acad Sci U S
580 A. 2019;116(18):9014-9. Epub 2019/04/18. doi: 10.1073/pnas.1902510116. PubMed PMID: 30992375; PubMed

581 Central PMCID: PMC6500118.
582 48. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
583 heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92(12):5510-4. Epub 1995/06/06.
584 PubMed PMID: 7539918; PubMed Central PMCID: PMC41725.
585 49. Simon MC, Keith B. The role of oxygen availability in embryonic development and stem cell function. Nat
586 Rev Mol Cell Biol. 2008;9(4):285-96.
587 50. Dunwoodie SL. The role of hypoxia in development of the Mammalian embryo. Dev Cell. 2009;17(6):755-
588 73. doi: 10.1016/j.devcel.2009.11.008. PubMed PMID: 20059947.
589 51. Stiles J, Jernigan TL. The basics of brain development. Neuropsychol Rev. 2010;20(4):327-48. doi:
590 10.1007/s11065-010-9148-4. PubMed PMID: 21042938; PubMed Central PMCID: PMC2989000.
591 52. Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science. 2015;349(6255):1483-
592 9. Epub 2015/09/26. doi: 10.1126/science.aab4082. PubMed PMID: 26404825.
593 53. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics.
594 2010;26(5):589-95. doi: 10.1093/bioinformatics/btp698. PubMed PMID: 20080505; PubMed Central PMCID:
595 PMC2828108.
596 54. Genomes Project C, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map
597 of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56-65. doi: 10.1038/nature11632.
598 PubMed PMID: 23128226; PubMed Central PMCID: PMC3498066.

599

600 # Supporting information

601 **S1 Appendix. Supplementary Methods.** The details of the methods in this study.

602 **S2 Appendix. Supplementary Notes.** The minor analysis and results in this study.

603 **S1 Fig. Pipeline for postzygotic mutation detection.**

604 **S2 Fig. Shared mutations among individuals and in time point samples of M0038.**

605 **S3 Fig. The distribution of variant allele fraction in each individual.**

606 **S4 Fig. QQ plot of the mutation fractions between simulation and observed in healthy individuals.**

607 **S5 Fig. Mutation type distribution in each individual.**

608 **S6 Fig. Mutation numbers of NpCpG and GpCpN among individuals of different ages.**

609 **S7 Fig. Replication asymmetry of each mutation type.**

610 **S8 Fig. Transcription asymmetry of each mutation type.**

611 **S9 Fig. Somatic mutation patterns in muscle.**

612 **S10 Fig. Somatic mutation patterns in TCGA samples.**

613 **S11 Fig. WA07 cells cultured with ML228 showed high fraction of C>T transitions at GpCpN context.**

614 **S12 Fig. The amounts of detected somatic mutations before and after repair mix treated.**

615 **S13 Fig. The distribution of inherited variant fraction.**

616 **S14 Fig. The mutational spectrum of recurrent glioblastoma.**

617 **S15 Fig. The mutational spectrum of normal neurons.**

618 **S16 Fig. The mutational spectrum of de novo mutations.**

619 **S17 Fig. The distribution of priori trinucleotide-specific sequencing error rate.**

620 **S18 Fig. The evaluation of mutagenic DNA damage induced sequencing error.**

621 **S19 Fig. Sequencing validation by duplicate reads.**

622 **S20 Fig. Possible bias among sequencing methods.**

623 **S21 Fig. The signature of hypermutated glioblastoma samples.**

624 **S22 Fig. The mutational signature of recurrent glioblastoma excluding hypermutated samples.**

625 **S23 Fig. No significant difference on DNA methylation was observed in CCRCC with high or low**

626 **GpCpC mutations.**

627 **S24 Fig. The VHL mutation hotspots in high or low GpCpC group in CCRCC.**

628 **S1 Table. Sequenced healthy individuals.**

629 **S2 Table. Shared mutations in time point samples of M0038.**

630 **S3 Table. Validation list of mutations in the study.**

631 **S4 Table. Shared mutations among individuals.**

632 **S5 Table. Proportion of samples with C>T at GpCpC site as the major type in various cancers.**

633 **S6 Table. Mutations of VHL in CCRCC samples.**

634 **S7 Table. Features of somatic mutations compared with inherited mutations.**

635 **S8 Table. Somatic and inherited mutations of M0038.**

636 **S9 Table. Somatic and inherited mutations of F0061.**

637 **S10 Table. Somatic and inherited mutations of M0070.**

638 **S11 Table. Somatic and inherited mutations of M0072.**

639 **S12 Table. Somatic and inherited mutations of M0074.**

640 **S13 Table. Population frequency of mutations found in dbSNP (healthy individuals).**

641 **S14 Table. Population frequency of mutations found in dbSNP (TCGA).**


A
Egg
Sperm
1
Fertilized Egg
36
Blood cells
4
16
Sperm
216
111
135
364
203
33 years old
36 years old
34 years old
35 years old
36 years old
C
Merged all
Simulation M0038
Blood (33) M0038
Blood (36) M0038
Sperm (34)
M0038 Sperm (35)
M0038 Sperm (36)
M0038 Muscle (37)
F0061 Blood (22)
M0070 Blood (13)
M0072 Blood (10)
M0074 Blood (5)
Density of mutation fraction
0.00
0.25
0.50
0.75
1.00
0
0.05
0.10
0.15
0.20
Mutation fraction
B
M0038 Blood (33 years old)
M0038 Blood (36 years old)
M0038 Sperm (34 years old)
M0038 Sperm (35 years old)
M0038 Sperm (36 years old)
CEP95
FAT3
OR2G6
NEB
DNHD1
KMT2D
HPCA
SLC4A1AP
COL7A1
MBD4
P2RY1
PDHA2
SPEF2
C5orf42
EPHA1
RIMS2
PLEC
TMEM215
KIAA1161
PIK3AP1
CASC1
NFE2
ACSS3
OR10G3
MPP5
DNAH3
GPR179
FN3KRP
OLFM2
ZNF211
NF2
EP300
UNC80
GPR156
HECW1
DENND4C
GPR158
PCNXL3
HECTD4
HELZ2
TBC1D9
GPANK1
NLRX1
WNT5B
SRRM2
PIK3CD
UQCRH
AP4B1
GBA3
ZNF311
DERL1
SETX
PUS1
GHDC
TRIP10
TCF20
Alternative allele fraction
0.500
0.400
0.300
0.200
0.100
0.020
0.015
0.010
0.005
0.000

Fig 1


A
C>A
C>G
C>T
T>A
T>C
T>G
M0038 Sperm (36 years old)
M0038 Sperm (35 years old)
M0038 Sperm (34 years old)
M0038 Blood (36 years old)
M0038 Blood (33 years old)
F0061 Blood (22 years old)
M0070 Blood (13 years old)
M0072 Blood (10 years old)
M0074 Blood (5 years old)
5' base
3' base
% of all mutations
50
40
30
20
10
0
B
% of Each Mutation Type
Total
C>T
G>A
Replication Direction
Right−Replicating
Left−Replicating
C
Transcription Direction
Sense Strand
Antisense Strand

Fig 2


A
C>A
C>G
C>T
T>A
T>C
T>G
Blood
Sperm
Muscle
Skin
Brain
% of all mutations
50
40
30
20
10
0
ESCC
ESCC Paired Blood
Chordoma
Chordoma Paired Blood
AML paired T Lymphocyte
CCRCC
CCRCC (High GpCpC)
5' base
3' base
B
Signature A
Signature B
Signature C
0.0
0.2
0.4
C>A
C>G
C>T
T>A
T>C
T>G
D
−log10(p−value)
Chromosome
C
Percentage contribution to the total variant number
100%
75%
50%
25%
0%
Signature A
Signature B
Signature C

Fig 3


A
AML paired T Lymphocyte
CCRCC (High GpCpC)
Chordoma Paired Blood
Sperm
ESCC Paired Blood
Blood
Skin
ESCC
Chordoma
CCRCC
0.8
0.6
0.4
0.2
0
B
Differently Expressed Genes
CCRCC (High GCC)
CCRCC (Relative low GCC)
Individual
C
−log (P−value)
4.0
3.5
3.0
2.5
2.0
JUND
MC2R
MCTP1
TRIM45
ITGA7
EXOSC6
KIAA1683
GAB4
IDI2
LETM2
MAFF
MCL1
OR4K17
PPARD
SLC36A4
SNED1
C17orf105
MRVI1
SLCO1C1
ZBTB10
DDX17
B3GALT1
FSD1
OR4K5
VPS37B
ABCC12
C1orf49
KLF2
CACNB2
DLL1
PPP1R12A
Differentially Expressed Genes

Fig 4


A
ML228
(0.125 nmol/ml)
ML228
(0.125 nmol/ml)
~ 1, 000 cells
10 cells
~ 1, 000 cells
Whole exome sequencing
WA07
Cultured 15 days with treatment
Randomly selected ~10 cells
Cultured 10 days with treatment
Mock control
Mock control
~ 1, 000 cells
10 cells
~ 1, 000 cells
Whole exome sequencing
B
C>A
C>G
C>T
T>A
T>C
T>G
5' base
T
G
C
A
WA07 (Control)
WA07 (ML228)
A C G T
3' base
% of all mutations
6
4
2
0
C
C>A
C>G
C>T
T>A
T>C
T>G
5' base
T
G
C
A
A C G T
3' base
% of change
8
4
0
−4
−8

Fig 5


Fertilization
Umbilical Cord Generation
3 Day Compaction
42 Day
After Birth
Neoplasia (CCRCC)
Spontaneous deamination C>T at NpCpG
Hypoxia C>T at GpCpN
Unknown etiology T>A
Unknown etiology T>C
Mismatch repair error

Fig 6